文献速递慢性肾脏病水电解质与酸碱

CKD-MBD生物标志物与CKD进展:联合模型分析

CKD-MBD biomarkers and CKD progression: an analysis by the joint model.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

该研究对729例2-5期CKD患者随访36个月,采用联合模型分析CKD-MBD生物标志物重复测量值与复合肾脏终点(eGFR下降>30%、透析或移植)的纵向关系。结果显示,纵向系列PTH、血磷、血钙及基线FGF23和1,25-二羟维生素D均与肾脏事件风险独立相关。

要点

  • 纵向系列PTH升高与肾脏事件风险独立正相关(HR 2.0,P<.001)。
  • 重复测量血磷升高与肾脏事件风险正相关(HR 1.3924,P=.001)。
  • 重复测量血钙升高与肾脏事件风险负相关(HR 0.7487,P=.022)。

核心结论

  • 在2-5期CKD患者队列中,血清PTH、钙和磷的重复测量值以及基线FGF23和1,25-二羟维生素D均与进展至肾衰竭独立相关。
  • 该纵向研究提出假设:对MBD生物标志物进行多层面干预可减轻该人群的肾功能丧失。

研究设计与样本

  • 研究纳入729例2-5期CKD患者,随访36个月,采用联合模型(JM)分析CKD-MBD生物标志物重复测量值与复合肾脏终点(eGFR下降>30%、透析或移植)的纵向关系。

主要发现

  • 在联合模型的生存子模型中,纵向系列PTH值与肾脏事件风险直接且独立相关(HR 2.0,范围1.5-2.8,P<.001)。
  • 重复测量血清磷酸盐与肾脏事件风险相关(HR 1.3924,范围1.1459-1.6918,P=.001)。
  • 重复测量血清钙与肾脏事件风险相关(HR 0.7487,范围0.5843-0.9593,P=.022)。
  • 基线成纤维细胞生长因子23与肾脏事件风险相关(HR 1.001,范围1.00-1.002,P=.045)。
  • 基线1,25-二羟维生素D与肾脏事件风险相关(HR 0.9796,范围0.9652-0.9942,P=.006)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biomarkers of chronic kidney disease-mineral and bone disorder (CKD-MBD) have been implicated in CKD progression in follow-up studies focusing on single measurements of individual biomarkers made at baseline only. The simultaneous relationship between the time trend of these biomarkers over the course of CKD and renal outcomes has never been tested. METHODS: We applied the joint model (JM) to investigate the longitudinal relationship between repeated measurements of CKD-MBD biomarkers and a combined renal endpoint (estimated glomerular filtration rate reduction >30%, dialysis or transplantation) in 729 stage 2-5 CKD patients over a 36-month follow-up. RESULTS: In the survival submodel of the JM, the longitudinal series of parathyroid hormone (PTH) values was directly and independently related to the risk of renal events [hazard ratio (HR) (1 ln increase in parathyroid hormone (PTH) 2.0 (range 1.5-2.8), P < .001)] and this was also true for repeated measurements of serum phosphate [HR (1 mg/dl) 1.3924 (range 1.1459-1.6918), P = .001], serum calcium [HR (1 mg/dl) 0.7487 (range 0.5843-0.9593), P = .022], baseline fibroblast growth factor 23 [HR (1 pg/ml) 1.001 (range 1.00-1.002), P = .045] and 1,25-dihydroxyvitamin D [HR (1 pg/ml) 0.9796 (range 0.9652-0.9942), P = .006]. CONCLUSION: Repeated measurements of serum PTH, calcium and phosphate as well as baseline FGF23 and 1,25-dihydroxyvitamin D are independently related with the progression to kidney failure in a cohort of stage 2-5 CKD patients. This longitudinal study generates the hypothesis that interventions at multiple levels on MBD biomarkers can mitigate renal function loss in this population.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. D'Arrigo G, Mallamaci F, Pizzini P, et al. CKD-MBD biomarkers and CKD progression: an analysis by the joint model. Nephrol Dial Transplant. 2023. PMID: 35790138. doi:10.1093/ndt/gfac212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。